congresses-banner

The content contained is subject

PublicationView

Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
Breast Cancer
A health-related quality of life (QOL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) versus capecitabine (CAP) in patients with hormone receptor–positive (HR+), HER2-low metastatic breast cancer (mBC)
Naoto Ueno
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND
Joyce O’Shaughnessy
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
Breast Cancer
A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
Hitomi Sakai
Oral
T-DXd
ASCO 2024 | May 31 - June 4, 2024
Breast Cancer
A randomized study comparing electronic patient-reported outcomes monitoring with routine follow-up during trastuzumab deruxtecan treatment for inoperable or metastatic breast cancer patients: PRO-DUCE study
Yuichiro Kikawa
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Breast Cancer
A retrospective study to investigate the prevalence and treatment outcomes of HER2-low unresectable/metastatic breast cancer in Taiwan — the RetroBC-HER2L-TW study
Ling-Ming Tseng
Poster
T-DXd
Miami Breast 2024 | March 7-10, 2024
Breast Cancer
Addressing barriers to identifying HER2-low metastatic breast cancer patients in a large community oncology practice
Lauren Carpenter
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
An open-label, interventional, multicenter study of trastuzumab deruxtecan monotherapy in patients with unresectable and/or metastatic HER2-low or HER2 immunohistochemistry 0 breast cancer: DESTINY-Breast15
Shanu Modi
Poster
Other/Multi
SABCS 2023 | December 5-9, 2023
Breast Cancer
Attrition rates from first- to third-line therapy in HER2+ metastatic breast cancer in Europe
Peter S. Hall
Poster
T-DXd
SABCS 2023 | December 5-9, 2023
Breast Cancer
Blocking soluble TNF to improve potency of trastuzumab deruxtecan by increasing internalization and antitumor innate immune response in a resistant HER2-positive breast cancer model
Sofia Bruni
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Breast Cancer
Clinical characteristics of patients with HER2+ unresectable or metastatic breast cancer: HER2 REAL Asia cohort
Soo Chin Lee
Páginas: 1  2  3  4  5  6  7  

footer